An eflornithine composition for inhibiting hair growth
AssigneeNavin Saxena Research and Technology Private Limited
InventorsKunal SAXENA, Navin SAXENA
Life of this patent
Estimating the term…
Abstract
The present invention discloses a topical cream composition of eflornithine or its pharmaceutically acceptable salts or prodrugs thereof with lavender oil as penetration enhancer and other excipients, which is effective to reduce the rate of skin hair growth and studies pertaining to pharmacodynamic behaviour thereof on hair growth rate. The invention further discloses a process for preparing a topical composition in the form of oil-in-water emulsion based cream composition which comprises eflornithine or its pharmaceutically acceptable salts or prodrugs thereof with a penetration enhancer and other excipients.
Claims21
A topical cream composition, effective to reduce the rate of skin hair growth, wherein the composition comprises:
- a) eflornithine, a pharmaceutically acceptable salt thereof, or a prodrug thereof at a concentration of about 3% w/w to 13.9% w/w of total composition,
- b) a penetration enhancer at a concentration of about 0.1% w/w to about 25.0% w/w of total composition,
- c) an oil in water emulsifier at a concentration of about 1.0% w/w to about 12.0% w/w of total composition,
- d) an emulsion stabiliser at a concentration of about 3.75% w/w to about 12.0% w/w of total composition,
- e) an emulsifier at a concentration of about 1.0% w/w to about 12.0% w/w of total composition,
- f) a defoaming agent at a concentration of about 1.0% w/w to about 9.0% w/w of total composition,
- g) a moisturizing and/or buffering agent at a concentration of about 0.01% w/w to about 2.0% w/w of total composition,
- h) a preservative at a concentration of about 0.1% w/w to about 0.8% w/w of total composition and
- i) a topical carrier.
(canceled)
The topical composition as claimed in claim 14, wherein the penetration enhancer is lavender oil.
The topical composition as claimed in claim 15, wherein the oil in water emulsifier is selected from the group consisting of glyceryl stearate and macrogol stearate.
The topical composition as claimed in claim 16, wherein the emulsion stabiliser is selected from the group consisting of cetostearyl alcohol and macrogol cetostearyl ether.
The topical composition as claimed in claim 15, wherein the emulsifier is stearyl alcohol.
The topical composition as claimed in claim 17, wherein the defoaming agent is polydimethylsiloxane.
The topical composition as claimed in claim 18, wherein the moisturizing and/or buffering agent is citric acid anhydrous.
The topical composition as claimed in claim 19, wherein the preservative is methyl paraben or propyl paraben.
A process for preparing a topical composition of eflornithine, a pharmaceutically acceptable salt thereof, or a prodrug thereof, comprising the steps of:
- a) preparing an oil phase by transferring glyceryl stearate and macrogol stearate, ceteostearyl alcohol and macrogol ceto stearyl ether, light liquid paraffin, stearyl alcohol and poly dimethyl siloxane in jacketed oil phase vessel,
- b) adding methyl paraben and propyl paraben to the melted mass by continuous stirring at a temperature of 50° C. to 90° C.,
- c) adding lavender oil slowly into the melted mass by continuous stirring,
- d) preparing an aqueous phase by transferring exactly half dispensed quantity of purified water and heating to a temperature of 60° C. to 65° C. and citric acid is added with continuous stirring to get a clear solution,
- e) adding the oil phase to the aqueous phase by maintaining the temperature to 70° C. to 80° C. to obtain an oil-in-water phase,
- f) Preparing a drug solution phase by adding eflornithine hydrochloride monohydrate to the remaining half-quantity of purified water with continuous stirring,
- g) Adding the drug solution phase to the oil-in-water phase with continuous stirring by maintaining the temperature to 40° C. to 80° C. to produce a mixture, and
- h) Cooling the mixture of step (g) to room temperature with continuous stirring till the mixture congeals to produce the topical composition of eflornithine as a cream, and maintaining the pH to 2 to 7.
(canceled)
Dependencies are inferred from the claim text.